ID   11-18
AC   CVCL_6659
AS   CVCL_A596
SY   II-18
DR   CLO; CLO_0050051
DR   BioSample; SAMN03472059
DR   cancercelllines; CVCL_6659
DR   Cell_Model_Passport; SIDM01637
DR   CGH-DB; 201-1
DR   CGH-DB; 9163-4
DR   Cosmic; 889084
DR   Cosmic; 946048
DR   Cosmic; 1066156
DR   Cosmic; 1239901
DR   Cosmic; 1336877
DR   Cosmic; 1656892
DR   Cosmic; 1731372
DR   Cosmic; 2125265
DR   IARC_TP53; 28444
DR   RCB; RCB2093
DR   TKG; TKG 0177
DR   Wikidata; Q54897419
RX   PubMed=9023415;
RX   PubMed=9538136;
RX   PubMed=14581340;
RX   PubMed=15746151;
RX   PubMed=16105816;
RX   PubMed=19472407;
RX   PubMed=20557307;
RX   PubMed=22313637;
RX   PubMed=22815900;
CC   Population: Japanese.
CC   HLA typing: A*02:01,24:02; B*52:01,54:01; C*01:02,12:01 (PubMed=9023415).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (PubMed=16105816).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Unspecified (PubMed=20557307).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 7,12 (RCB)
ST   CSF1PO: 12 (TKG)
ST   D13S317: 12
ST   D16S539: 10
ST   D5S818: 10,12
ST   D7S820: 11
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9538136; DOI=10.3892/ijo.12.5.1103;
RA   Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H.,
RA   Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.;
RT   "Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-
RT   3 peptide recognized by cytotoxic T lymphocytes.";
RL   Int. J. Oncol. 12:1103-1109(1998).
//
RX   PubMed=14581340;
RA   Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.;
RT   "TERC identified as a probable target within the 3q26 amplicon that is
RT   detected frequently in non-small cell lung cancers.";
RL   Clin. Cancer Res. 9:4705-4713(2003).
//
RX   PubMed=15746151; DOI=10.1093/hmg/ddi092;
RA   Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in
RT   non-small cell lung cancers.";
RL   Hum. Mol. Genet. 14:997-1007(2005).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//
RX   PubMed=22815900; DOI=10.1371/journal.pone.0041017;
RA   Tabara K., Kanda R., Sonoda K., Kubo T., Murakami Y., Kawahara A.,
RA   Azuma K., Abe H., Kage M., Yoshinaga A., Tahira T., Hayashi K.,
RA   Arao T., Nishio K., Rosell R., Kuwano M., Ono M.;
RT   "Loss of activating EGFR mutant gene contributes to acquired
RT   resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.";
RL   PLoS ONE 7:E41017-E41017(2012).
//